From 355ff2d5d1ef02a5effe0213f4110be84bd1cede Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 3 Apr 2026 14:15:37 +0000 Subject: [PATCH] extract: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...becoming-leading-contributing-cvd-cause.md | 6 ++++ ...ilability-is-not-the-binding-constraint.md | 6 ++++ ...ng-heart-failure-hypertension-worsening.md | 34 +++++++++++++++++++ ...aseline-despite-acute-care-improvements.md | 6 ++++ ...-heart-disease-stroke-statistics-update.md | 17 +++++++++- 5 files changed, 68 insertions(+), 1 deletion(-) create mode 100644 domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md diff --git a/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md index bf3a7144..21382a84 100644 --- a/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md +++ b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md @@ -15,3 +15,9 @@ related_claims: ["[[Big Food companies engineer addictive products by hacking ev # Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of death in the US. The mechanism is structural: obesity prevalence, sedentary behavior, and metabolic syndrome create a treatment-resistant hypertension burden that pharmacological interventions (ACE inhibitors, ARBs, diuretics) can manage but not eliminate. The geographic and demographic pattern confirms this: increases are disproportionate in Southern states (higher baseline obesity, lower healthcare access), Black Americans (structural hypertension treatment gap), and rural vs. urban areas. This represents a fundamental divergence from ischemic heart disease, which declined over the same period due to acute care improvements (stenting, statins). The bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers of hypertensive disease. The doubling occurred despite widespread availability of effective antihypertensive medications, indicating the problem is behavioral and structural, not pharmaceutical. + +### Additional Evidence (confirm) +*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* + +AHA 2026 statistics confirm hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 (1999-2023) and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This is the definitive annual data source confirming the trend. + diff --git a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md index 29e6f627..f66eb750 100644 --- a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md +++ b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md @@ -48,6 +48,12 @@ The systematic review establishes that the binding constraints are SDOH-mediated Boston food-as-medicine RCT achieved BP improvement during active 12-week intervention but complete reversion to baseline 6 months post-program, confirming that the binding constraint is structural food environment, not medication availability or patient knowledge. Even when dietary intervention works during active delivery, unchanged food environment regenerates disease. +### Additional Evidence (confirm) +*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* + +The AHA 2026 report notes that 1 in 3 US adults has hypertension and hypertension control rates have worsened since 2015, occurring simultaneously with hypertensive disease mortality doubling. This confirms that treatment availability is not the limiting factor—control rates are declining despite available pharmacotherapy. + + diff --git a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md new file mode 100644 index 00000000..239fdd44 --- /dev/null +++ b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md @@ -0,0 +1,34 @@ +--- +type: claim +domain: health +description: The divergent trends by CVD subtype reveal that excellent acute ischemic care coexists with worsening chronic cardiometabolic burden +confidence: experimental +source: American Heart Association 2026 Statistics Update, 2023 data +created: 2026-04-03 +attribution: + extractor: + - handle: "vida" + sourcer: + - handle: "american-heart-association" + context: "American Heart Association 2026 Statistics Update, 2023 data" +--- + +# US CVD mortality is bifurcating with ischemic heart disease and stroke declining while heart failure and hypertensive disease worsen creating aggregate improvement that masks structural deterioration in cardiometabolic health + +The AHA 2026 statistics reveal a critical bifurcation pattern in US cardiovascular mortality. While overall age-adjusted CVD mortality declined 2.7% from 2022 to 2023 (224.3 → 218.3 per 100,000) and has fallen 33.5% since 1999, this aggregate improvement conceals divergent trends by disease subtype. + +Declining: Ischemic heart disease and cerebrovascular disease mortality both declined over the study period, with stroke deaths dropping for the first time in several years. + +Worsening: Heart failure mortality reached an all-time high of 21.6 per 100,000 in 2023—exceeding its 1999 baseline of 20.3 after declining to 16.9 in 2011. This represents a complete reversal, not stagnation. Hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023, and since 2022 has become the #1 contributing cardiovascular cause of death, surpassing ischemic heart disease. + +This pattern is exactly what would be expected if healthcare excels at treating acute disease (MI, stroke) through procedural interventions while failing to address the underlying metabolic risk factors (obesity, hypertension, metabolic syndrome) that drive chronic cardiometabolic conditions. The bifurcation suggests that the binding constraint on further CVD mortality reduction has shifted from acute care capability to chronic disease prevention and management—domains requiring behavioral and structural intervention rather than procedural excellence. + +--- + +Relevant Notes: +- [[hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause]] +- [[us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements]] +- [[hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure]] + +Topics: +- [[_map]] diff --git a/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md index 37c53a08..fefffab8 100644 --- a/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md +++ b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md @@ -15,3 +15,9 @@ related_claims: ["[[Americas declining life expectancy is driven by deaths of de # US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes. + +### Additional Evidence (confirm) +*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* + +2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation. + diff --git a/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md b/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md index e93a8a97..4c5b5a46 100644 --- a/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md +++ b/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md @@ -7,9 +7,14 @@ date: 2026-01-21 domain: health secondary_domains: [] format: research-paper -status: unprocessed +status: processed priority: high tags: [cardiovascular-disease, mortality-trends, heart-failure, hypertension, ischemic-heart-disease, US-statistics, belief-1, belief-3, CVD-stagnation, bifurcation] +processed_by: vida +processed_date: 2026-04-03 +claims_extracted: ["us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md"] +enrichments_applied: ["hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md", "us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md", "only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -64,3 +69,13 @@ The 2026 report covers data through 2023 — before the 2024 life expectancy rec PRIMARY CONNECTION: Abrams AJE 2025 (CVD stagnation pervasive); CDC 2026 life expectancy record; PNAS Shiels 2020 (CVD primary driver) WHY ARCHIVED: Confirms and extends CVD stagnation pattern with 2023 data; reveals HF at all-time high (new finding not in KB); establishes bifurcation pattern (ischemic declining, HF/HTN worsening) that explains why aggregate life expectancy improvement masks structural deterioration EXTRACTION HINT: The bifurcation finding is the novel claim: US CVD mortality is diverging by subtype in a way that masks structural worsening behind aggregate improvement. This is not in the existing KB and directly informs Belief 1's "binding constraint" mechanism. + + +## Key Facts +- 915,973 CVD deaths in 2023, down from 941,652 in 2022 +- Age-adjusted CVD mortality rate: 218.3 per 100,000 in 2023 vs 224.3 in 2022 (~2.7% decline) +- 33.5% overall decline in age-adjusted CVD mortality since 1999 (350.8 → 218.3 per 100,000) +- 2021 pandemic spike: CVD mortality rate rose to 233.3 before resuming decline +- 48 million Americans have cardiovascular disease +- Heart disease remains the leading cause of death in the US; stroke moved to #4 +- CVD claims more lives annually than causes #2 and #3 combined (cancer and accidents)